SEC Tracker
Get the app
ANIX · XBRL financial data

Anixa Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ANIX's year ends in late October)

In thousands of dollarsOct 31, 2023Jan 31, 2024Apr 30, 2024Jul 31, 2024Oct 31, 2024Jan 31, 2025Apr 30, 2025Jul 31, 2025Oct 31, 2025Jan 31, 2026Apr 30, 2026Jul 31, 2026
Revenue0*———year only———————
Revenue from contracts with customers0*———————————
Research and development1,615*1,3491,6461,9251,476*1,5521,3221,0551,142*1,1021,2581,326
General and administrative1,436*2,2601,8211,6671,687*1,8341,6811,3811,734*1,6141,3891,411
Operating income (loss)(3,051)*(3,609)(3,467)(3,592)(3,163)*(3,386)(3,003)(2,436)(2,876)*(2,716)(2,647)(2,737)
Net income (loss)(2,690)*(3,255)(3,139)(3,277)(2,883)*(3,184)(2,790)(2,258)(2,695)*(2,565)(2,516)(2,606)
Earnings per share, basic USD per share—0.10(0.10)(0.10)—(0.10)(0.09)(0.07)—(0.08)(0.07)(0.08)
Earnings per share, diluted USD per share—0.10(0.10)(0.10)—(0.10)(0.09)(0.07)—(0.08)(0.07)(0.08)
Weighted average shares, basic thousands of shares31*31323232*32,19732,20232,476—33,24033,59334,182
Weighted average shares, diluted thousands of shares31*31323232*32,19732,20232,476—33,24033,59334,182

Balance sheet

CSV

Fiscal quarters (ANIX's year ends in late October)

In thousands of dollarsOct 31, 2023Jan 31, 2024Apr 30, 2024Jul 31, 2024Oct 31, 2024Jan 31, 2025Apr 30, 2025Jul 31, 2025Oct 31, 2025Jan 31, 2026Apr 30, 2026Jul 31, 2026
Cash and cash equivalents9159989951,2251,2711,0531,9101,4951,2441,5471,4771,398
Short-term investments22,92922,80022,24419,52018,65316,20213,68714,53413,93012,65512,20912,466
Prepaid and other current assets1,2421,0307571,5151,2651,4311,1691,4207138489501,047
Total current assets25,35625,21924,21422,67021,36218,68616,76617,44915,88715,05014,69214,911
Right-of-use asset166153141238229220211202193183173163
Total assets25,52225,37224,35522,90821,59118,90616,97717,65116,08015,23314,86515,074
Accounts payable206364215302525600284276165148252282
Accrued liabilities1,7701,2421,4101,6781,9461,3631,5661,7511,7611,0461,2051,417
Total current liabilities2,0281,6601,6812,0042,5001,9991,8872,0661,9671,2361,5011,745
Lease liability, non-current12310893213203194184174163151140128
Total liabilities2,1511,7681,7742,2172,7032,1932,0712,2402,1301,3871,6411,873
Accumulated deficit(228,196)(231,451)(234,590)(237,867)(240,750)(243,934)(246,724)(248,982)(251,677)(254,242)(256,758)(259,364)
Total stockholders' equity24,33724,60523,62321,77119,99817,85216,06816,59515,16115,07714,47514,471
Total liabilities and equity25,52225,37224,35522,90821,59118,90616,97717,65116,08015,23314,86515,074
Common shares outstanding (cover page) thousands of shares31,70031,90032,00632,17932,19732,19732,21132,91733,37733,52834,02334,764

Cash flows

CSV

Fiscal quarters (ANIX's year ends in late October)

In thousands of dollarsOct 31, 2023Jan 31, 2024Apr 30, 2024Jul 31, 2024Oct 31, 2024Jan 31, 2025Apr 30, 2025Jul 31, 2025Oct 31, 2025Jan 31, 2026Apr 30, 2026Jul 31, 2026
Net income (loss)(2,690)*(3,255)(3,139)(3,277)(2,883)*(3,184)(2,790)(2,258)(2,695)*(2,565)(2,516)(2,606)
Stock-based compensation1,157*1,1081,238*1,094*980*1,031962*829*859*768637*637*
Net cash from operating activities(1,969)*(2,309)(1,456)*(2,643)*(927)*(2,904)(1,503)*(1,511)*(1,255)*(2,610)(1,741)*(1,770)*
Net cash from investing activities(593)*129556*2,724*867*2,7032,342*(833)*654*1,228422*(245)*
Proceeds from issuing common stock—2,196833*(45)*(29)*(17)14*1,927*454*——1,936*
Share repurchases————year only———————
Net cash from financing activities279*2,263897*149*106*(17)18*1,929*350*1,6851,249*1,936*
Net change in cash(2,283)*83(3)*230*46*(218)857*(415)*(251)*303(70)*(79)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Anixa Biosciences1,398not reported(1,770)*34.8M6.8 quarters 10-QJul 31, 2026
Entera Bio11,3090(3,464)*173.1M3.3 quarters 10-QJun 30, 2026
Filana Therapeutics46,990not reported(6,094)*50.3M7.5 quarters 10-QSep 30, 2026
Immunic155,098not reported(30,998)*13.6M5.0 quarters 10-QJun 30, 2026
Coherus Oncology82,923not reported(62,090)*154.5M1.7 quarters 10-QJun 30, 2026
Elicio Therapeutics30,900not reported(10,364)*28.3M3.1 quarters 10-QSep 30, 2026
GENELUX9,184not reported(6,444)*45.2M2.9 quarters 10-QJun 30, 2026
Oramed Pharmaceuticals15,245not reported(200)*41.6M189.8 quarters 10-QJun 30, 2026
XBiotech109,528not reported(4,515)*30.5M24.3 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.